AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11084540 — intervention group
Group type: COMPARATOR
Intervention: Electronic fetal heart rate monitoring alone (control group)
Number of subjects: 1010
Study 9280211 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mmol/day potassium chloride for 7 days
Number of subjects: 24
Study 9280211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8518017 — intervention group
Group type: COMPARATOR
Intervention: Goserelin acetate alone
Number of subjects: 373
Study 8518017 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin acetate plus flutamide
Number of subjects: 373
Study 3470953 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel (Prepidil)
Number of subjects: 25
Study 3470953 — intervention group
Group type: COMPARATOR
Intervention: Artificial rupture of membranes combined with intravenous oxytocin
Number of subjects: 25
Study 29159599 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic mesh repair
Number of subjects: 102
Study 29159599 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic sutured repair
Number of subjects: 102
Study 27383186 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention (android phone with application for reminders and educational messages)
Number of subjects: 933
Study 27383186 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mHealth intervention)
Number of subjects: 933
Study 23839907 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 22
Study 22434266 — intervention group
Group type: EXPERIMENTAL
Intervention: preSevo 1 (1.0-1.1 vol% sevoflurane with pre-exposure to 1 vol% sevoflurane)
Number of subjects: 64
Study 22434266 — intervention group
Group type: EXPERIMENTAL
Intervention: preSevo 2 (1.2-1.3 vol% sevoflurane with pre-exposure to 1 vol% sevoflurane)
Number of subjects: 64
Study 22434266 — intervention group
Group type: COMPARATOR
Intervention: control 1 (1.0-1.1 vol% sevoflurane)
Number of subjects: 64
Study 22434266 — intervention group
Group type: COMPARATOR
Intervention: control 2 (1.2-1.3 vol% sevoflurane)
Number of subjects: 64
Study 22434266 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 64
Study 20163739 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy program including exercise and manual therapy (individual sessions once a week for 10 weeks and daily home exercises)
Number of subjects: 20
Study 20163739 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy program including exercise and manual therapy
Number of subjects: 20
Study 20163739 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20
Study 18752443 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 3282
Study 18752443 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ)
Number of subjects: 3282
Study 18752443 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine and Amodiaquine (SPAQ)
Number of subjects: 3282
Study 15804467 — intervention group
Group type: EXPERIMENTAL
Intervention: UWCores
Number of subjects: 14
Study 12877449 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 36
Study 12877449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 10967150 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular walking during a golf game
Number of subjects: 110
Study 8979525 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed-in questionnaire to study factors affecting initiation and quitting of smoking
Number of subjects: 10
Study 8979525 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of a smoker in the family
Number of subjects: 10
Study 8979525 — intervention group
Group type: EXPERIMENTAL
Intervention: Quitting smoking
Number of subjects: 10
Study 1437342 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine surfactant (50 mg/kg BW)
Number of subjects: 69
Study 1437342 — intervention group
Group type: COMPARATOR
Intervention: Control (no surfactant)
Number of subjects: 69
Study 3885671 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyprogesterone caproate (5000 mg i.m. as a loading dose followed by 1000 mg every 2 weeks for one year)
Number of subjects: 57
Study 3885671 — intervention group
Group type: COMPARATOR
Intervention: Surgery plus intravaginal irradiation (Control group A)
Number of subjects: 57
Study 3885671 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyprogesterone caproate
Number of subjects: 57
Study 29738817 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (aPDT) with open flap debridement (OFD)
Number of subjects: 24
Study 29738817 — intervention group
Group type: COMPARATOR
Intervention: Open flap debridement (OFD) alone
Number of subjects: 24
Study 28033320 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture (AA)
Number of subjects: 44
Study 28033320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 23713493 — intervention group
Group type: EXPERIMENTAL
Intervention: HMW protein
Number of subjects: 8
Study 23713493 — intervention group
Group type: EXPERIMENTAL
Intervention: LMW protein
Number of subjects: 8
Study 23713493 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein
Number of subjects: 8
Study 23713493 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein
Number of subjects: 8
Study 23713493 — intervention group
Group type: EXPERIMENTAL
Intervention: HMW and LMW proteins
Number of subjects: 8
Study 21840758 — intervention group
Group type: EXPERIMENTAL
Intervention: HCG triggering (Group A, n=30)
Number of subjects: 60
Study 21840758 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous ovulation (Group B, n=30)
Number of subjects: 60
Study 19794988 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg intravenous ephedrine
Number of subjects: 42
Study 19794988 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 42
Study 19794988 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study 17283177 — intervention group
Group type: EXPERIMENTAL
Intervention: APEX1 51H variant
Number of subjects: 767
Study 17283177 — intervention group
Group type: EXPERIMENTAL
Intervention: XRCC1 399Q variant
Number of subjects: 767
Study 17283177 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygotes at PARP1 loci (A284A and IVS13+118G>A)
Number of subjects: 767
Study 17283177 — intervention group
Group type: EXPERIMENTAL
Intervention: PARP1 A284A
Number of subjects: 767
Study 15080357 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric sulfate pulpotomy (FS)
Number of subjects: 130
Study 15080357 — intervention group
Group type: COMPARATOR
Intervention: Root canal therapy (RCT)
Number of subjects: 130
Study 11465585 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-guided, model-based, closed-loop system for propofol administration
Number of subjects: 20
Study 11465585 — intervention group
Group type: COMPARATOR
Intervention: Manual control of propofol administration using classical hemodynamic signs
Number of subjects: 20
Study 9622403 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-minute music therapy intervention
Number of subjects: 54
Study 9622403 — intervention group
Group type: COMPARATOR
Intervention: Rest period (control group)
Number of subjects: 54
Study 7878692 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 500 mg orally three times a day for 6 days
Number of subjects: 10
Study 7878692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2458438 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose chemotherapy (600 mg/m2 cyclophosphamide and fluorouracil, 40 mg/m2 methotrexate)
Number of subjects: 133
Study 2458438 — intervention group
Group type: COMPARATOR
Intervention: Lower-dose chemotherapy (300 mg/m2 cyclophosphamide and fluorouracil, 20 mg/m2 methotrexate)
Number of subjects: 133
Study 2458438 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose chemotherapy
Number of subjects: 133
Study 2458438 — intervention group
Group type: COMPARATOR
Intervention: Lower-dose chemotherapy
Number of subjects: 133
Study 2458438 — intervention group
Group type: COMPARATOR
Intervention: Crossover from lower-dose to higher-dose chemotherapy
Number of subjects: 133
Study 29643011 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir (50 mg oral once a day for 56 days)
Number of subjects: 40
Study 29643011 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral once a day for 56 days)
Number of subjects: 40
Study 28858440 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilazodone 40 mg/d
Number of subjects: 59
Study 28858440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 25851628 — intervention group
Group type: EXPERIMENTAL
Intervention: trastuzumab
Number of subjects: 429
Study 25851628 — intervention group
Group type: EXPERIMENTAL
Intervention: lapatinib
Number of subjects: 429
Study 25851628 — intervention group
Group type: EXPERIMENTAL
Intervention: trastuzumab and lapatinib combination
Number of subjects: 429
Study 24180295 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured and repeated multidisciplinary medication review supported by education and continuous evaluation.
Number of subjects: 360
Study 20972646 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional amino acid mixture (Aminotrofic®, Errekappa Euroterapici); 20% of estimated nitrogen requirements for 14 days
Number of subjects: 19
Study 20972646 — intervention group
Group type: COMPARATOR
Intervention: Standard protein supplement; 20% of estimated nitrogen requirements for 14 days
Number of subjects: 19
Study 18838923 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/fentanyl
Number of subjects: 22
Study 18838923 — intervention group
Group type: COMPARATOR
Intervention: Propofol/placebo
Number of subjects: 22
Study 21446378 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine-based regimen
Number of subjects: 93
Study 21446378 — intervention group
Group type: COMPARATOR
Intervention: Atenolol-based regimen
Number of subjects: 93
Study 15932657 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive strategy (coronary angiography performed within 48 hours)
Number of subjects: 910
Study 15932657 — intervention group
Group type: COMPARATOR
Intervention: Initially conservative strategy (coronary angiography performed after 48 hours)
Number of subjects: 910
Study 15932657 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive strategy with CABG
Number of subjects: 910
Study 12354133 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐T4 + I (iodized salt)
Number of subjects: 139
Study 12354133 — intervention group
Group type: COMPARATOR
Intervention: L‐T4 alone
Number of subjects: 139
Study 9834894 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% mequitazine eyedrops
Number of subjects: 40
Study 9834894 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% mequitazine eyedrops
Number of subjects: 40
Study 9834894 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 40
Study 8587426 — intervention group
Group type: EXPERIMENTAL
Intervention: ET-1 (nonselective agonist at ETA and ETB receptors)
Number of subjects: 0
Study 8587426 — intervention group
Group type: EXPERIMENTAL
Intervention: ET-3 (ETB receptor agonist)
Number of subjects: 0
Study 8587426 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarafotoxin S6c (ETB receptor agonist)
Number of subjects: 0
Study 2681488 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected goals
Number of subjects: 20
Study 2681488 — intervention group
Group type: COMPARATOR
Intervention: Assigned goals
Number of subjects: 20
Study 2681488 — intervention group
Group type: COMPARATOR
Intervention: Contingent gameplay conditions
Number of subjects: 20
Study 2681488 — intervention group
Group type: COMPARATOR
Intervention: Noncontingent gameplay conditions
Number of subjects: 20
Study 333761 — intervention group
Group type: EXPERIMENTAL
Intervention: Live mumps vaccine from L-3 strain, single injection of 10(4)HAdU50 of mumps virus.
Number of subjects: 1507
Study 333761 — intervention group
Group type: EXPERIMENTAL
Intervention: Live mumps vaccine from L-3 strain.
Number of subjects: 1507
Study 333761 — intervention group
Group type: COMPARATOR
Intervention: Convalescents from mumps infection.
Number of subjects: 1507
Study 29547081 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative diffusion tensor imaging (DTI) and diffusion tensor tractography (DTT)
Number of subjects: 47
Study 29547081 — intervention group
Group type: COMPARATOR
Intervention: Control group (no DTI/DTT)
Number of subjects: 47
Study 29547081 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative DTI/DTT
Number of subjects: 47
Study 27505115 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Number of subjects: 57
Study 27505115 — intervention group
Group type: COMPARATOR
Intervention: Standard bupivacaine
Number of subjects: 57
Study 24836868 — intervention group
Group type: EXPERIMENTAL
Intervention: Branded rifaximin (2×200mg)
Number of subjects: 24
Study 24836868 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic rifaximin (2×200mg)
Number of subjects: 24
Study 24836868 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 24
Study 22455828 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental intervention (multi-strategy intervention over 12 weeks)
Number of subjects: 241
Study 22455828 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 241
Study 20526759 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training for 10 weeks
Number of subjects: 27
Study 18672992 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue brushing and tooth brushing plus flossing
Number of subjects: 102
Study 18672992 — intervention group
Group type: COMPARATOR
Intervention: Tongue brushing and tooth brushing
Number of subjects: 102
Study 15683753 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment
Number of subjects: 57
Study 12854503 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose radiation therapy (10 fractions of 2 Gy external beam)
Number of subjects: 70
Study 12854503 — intervention group
Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 70
Study 10535384 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg octreotide per day for 6 months
Number of subjects: 27
Study 10535384 — intervention group
Group type: COMPARATOR
Intervention: Control group (unblinded)
Number of subjects: 27
Study 8984868 — intervention group
Group type: EXPERIMENTAL
Intervention: Bougie First Group (gum elastic bougie)
Number of subjects: 100
Study 8984868 — intervention group
Group type: COMPARATOR
Intervention: Stylet First Group (stylet)
Number of subjects: 100
Study 1682683 — intervention group
Group type: EXPERIMENTAL
Intervention: Active antihypertensive therapy (three beta-blockers and one diuretic)
Number of subjects: 1627
Study 1682683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1627
Study 7007473 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine 150 mg/day
Number of subjects: 95
Study 7007473 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine 24 mg/day
Number of subjects: 95
Study 7007473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 7007473 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine
Number of subjects: 95
Study 7007473 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine
Number of subjects: 95
Study 7007473 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine and Chlorpheniramine
Number of subjects: 95
Study 31362969 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic distribution
Number of subjects: 246
Study 31362969 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 246
Study 29448858 — intervention group
Group type: EXPERIMENTAL
Intervention: 3ABVD + involved-field (IF) low-dose (LD) irradiation (20 Gy) for GR1 patients with mediastinal mass or partial response after chemotherapy.
Number of subjects: 560
Study 29448858 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 COPP/ABV for GR2 patients.
Number of subjects: 560
Study 29448858 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 COPP/ABV for GR3 patients.
Number of subjects: 560
Study 29448858 — intervention group
Group type: COMPARATOR
Intervention: Response evaluated with conventional imaging (CI).
Number of subjects: 560
Study 26147464 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 6% 130/0.4
Number of subjects: 107
Study 26147464 — intervention group
Group type: COMPARATOR
Intervention: Ringer's solution
Number of subjects: 107
Study 24374068 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient treatment for 8 weeks
Number of subjects: 64
Study 24374068 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 64
Study 24374068 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient treatment
Number of subjects: 64
Study 22708638 — intervention group
Group type: COMPARATOR
Intervention: Standard lifestyle advice alone (control group)
Number of subjects: 580
Study 22708638 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle advice combined with genetic or phenotypic risk estimate for T2D (intervention groups)
Number of subjects: 580
Study 21162840 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 µg CHO hepatitis B vaccine
Number of subjects: 642
Study 21162840 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 µg CHO hepatitis B vaccine
Number of subjects: 642
Study 17852017 — intervention group
Group type: EXPERIMENTAL
Intervention: ALS Functional Rating Scale (ALSFRS‐R)
Number of subjects: 30
Study 17852017 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-perceived clinical function
Number of subjects: 30
Study 17852017 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced vital capacity
Number of subjects: 30
Study 17852017 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual muscle testing (MMT)
Number of subjects: 30
Study 17852017 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life assessments
Number of subjects: 30
Study 16061315 — intervention group
Group type: EXPERIMENTAL
Intervention: Locking palmar plating
Number of subjects: 53
Study 16061315 — intervention group
Group type: COMPARATOR
Intervention: Non-locking palmar plating
Number of subjects: 53
Study 12351591 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified CDE (cyclophosphamide 1,250 mg/m(2), doxorubicin 55 mg/m(2), etoposide 125 mg/m(2) with G-CSF 5 micro g/kg/d)
Number of subjects: 244
Study 12351591 — intervention group
Group type: COMPARATOR
Intervention: Standard CDE (cyclophosphamide 1,000 mg/m(2), doxorubicin 45 mg/m(2), etoposide 100 mg/m(2))
Number of subjects: 244
Study 11773880 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole gel
Number of subjects: 51
Study 11773880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 9690802 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid therapy (specific dosage and duration not mentioned)
Number of subjects: 61
Study 7710467 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate induction of labor (n = 265)
Number of subjects: 440
Study 7710467 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (n = 175)
Number of subjects: 440
Study 7710467 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel (0.5 mg)
Number of subjects: 440
Study 7710467 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 440
Study 7710467 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 440
Study 7710467 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel
Number of subjects: 440
Study 2511611 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of phenoxymethylpenicillin suspension
Number of subjects: 319
Study 2511611 — intervention group
Group type: COMPARATOR
Intervention: Standard formulation of phenoxymethylpenicillin suspension
Number of subjects: 319
Study 2511611 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 319
Study 323093 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium dobesilate
Number of subjects: 18
Study 323093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31238966 — intervention group
Group type: EXPERIMENTAL
Intervention: MS INFoRm website (intervention group)
Number of subjects: 200
Study 31238966 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group (control group)
Number of subjects: 200
Study 29029337 — intervention group
Group type: COMPARATOR
Intervention: >90% IRS protection
Number of subjects: 565
Study 25954938 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT) for 12 weeks
Number of subjects: 26
Study 25954938 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram (10 to 20 mg) for 12 weeks
Number of subjects: 26
Study 22900665 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Caries Dialogue (VCD) with comprehensive open discussion
Number of subjects: 230
Study 22900665 — intervention group
Group type: COMPARATOR
Intervention: Traditional oral healthcare information (Control)
Number of subjects: 230
Study 21810897 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril and atenolol as monotherapy
Number of subjects: 400
Study 19074756 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visitor education with GP participation in small group training
Number of subjects: 4034
Study 19074756 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visitor education
Number of subjects: 4034
Study 19074756 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention municipalities
Number of subjects: 4034
Study 19074756 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 4034
Study 16919064 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraineurs
Number of subjects: 56
Study 16919064 — intervention group
Group type: COMPARATOR
Intervention: Non-headache controls
Number of subjects: 56
Study 16919064 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraineurs and Non-headache controls
Number of subjects: 56
Study 15646943 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-headed toothbrush (group A)
Number of subjects: 29
Study 15646943 — intervention group
Group type: COMPARATOR
Intervention: Conventional toothbrush (group B)
Number of subjects: 29